Cargando…

Long‐term follow up of nivolumab in previously untreated Japanese patients with advanced or recurrent malignant melanoma

The immune checkpoint inhibitor nivolumab inhibits the programmed death 1 receptor and suppresses the immune resistance of cancer cells. This is a long‐term follow up of a single‐arm, open‐label, multicenter, phase II study of nivolumab in untreated Japanese patients with stage III/IV or recurrent m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yamazaki, Naoya, Kiyohara, Yoshio, Uhara, Hisashi, Uehara, Jiro, Fujisawa, Yasuhiro, Takenouchi, Tatsuya, Otsuka, Masaki, Uchi, Hiroshi, Ihn, Hironobu, Hatsumichi, Masahiro, Minami, Hironobu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6549931/ https://www.ncbi.nlm.nih.gov/pubmed/30959557 http://dx.doi.org/10.1111/cas.14015

Ejemplares similares

Five‐year survival with nivolumab in previously untreated Japanese patients with advanced or recurrent malignant melanoma
por: Uhara, Hisashi, et al.
Publicado: (2021)

Efficacy and safety of nivolumab in Japanese patients with previously untreated advanced melanoma: A phase II study
por: Yamazaki, Naoya, et al.
Publicado: (2017)

Cytokine biomarkers to predict antitumor responses to nivolumab suggested in a phase 2 study for advanced melanoma
por: Yamazaki, Naoya, et al.
Publicado: (2017)

Final analysis of a phase II study of nivolumab in combination with ipilimumab for unresectable chemotherapy‐naive advanced melanoma
por: Namikawa, Kenjiro, et al.
Publicado: (2020)

Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Japanese subgroup analysis from the phase 3 CheckMate 238 study
por: Yokota, Kenji, et al.
Publicado: (2019)

Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041)
por: Yamazaki, Naoya, et al.
Publicado: (2017)

Safety and effectiveness of nivolumab in Japanese patients with malignant melanoma: Final analysis of a post‐marketing surveillance
por: Uhara, Hisashi, et al.
Publicado: (2022)

Phase II study of the immune-checkpoint inhibitor ipilimumab plus dacarbazine in Japanese patients with previously untreated, unresectable or metastatic melanoma
por: Yamazaki, N., et al.
Publicado: (2015)

Phase I study of pegylated interferon‐alpha‐2b as an adjuvant therapy in Japanese patients with malignant melanoma
por: Yamazaki, Naoya, et al.
Publicado: (2016)

Real‐world safety and efficacy data of ipilimumab in Japanese radically unresectable malignant melanoma patients: A postmarketing surveillance
por: Yamazaki, Naoya, et al.
Publicado: (2020)

Exposure–Response Analysis of Nivolumab in Patients With Previously Treated or Untreated Advanced Melanoma
por: Bajaj, Gaurav, et al.
Publicado: (2017)

Randomized phase III trial of adjuvant therapy with locoregional interferon beta versus surgery alone in stage II/III cutaneous melanoma: Japan Clinical Oncology Group Study (JCOG1309, J-FERON)
por: Namikawa, Kenjiro, et al.
Publicado: (2017)

Prospective observational study of the efficacy of nivolumab in Japanese patients with advanced melanoma (CREATIVE study)
por: Yamazaki, Naoya, et al.
Publicado: (2021)

A randomized phase 2 trial of nivolumab, gemcitabine, and cisplatin or nivolumab and ipilimumab in previously untreated advanced biliary cancer: BilT‐01
por: Sahai, Vaibhav, et al.
Publicado: (2022)

Transition of the PD-1 occupancy of nivolumab on T cells after discontinuation and response of nivolumab re-challenge
por: Nose, Taku, et al.
Publicado: (2022)

Significance of 5-S-Cysteinyldopa as a Marker for Melanoma
por: Wakamatsu, Kazumasa, et al.
Publicado: (2020)

Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma
por: Yamazaki, N., et al.
Publicado: (2015)

Clinical and histopathological characteristics and survival analysis of 4594 Japanese patients with melanoma
por: Fujisawa, Yasuhiro, et al.
Publicado: (2019)

Myasthenic crisis and polymyositis induced by one dose of nivolumab
por: Kimura, Toshihiro, et al.
Publicado: (2016)

Clinical Significance of Serum Vascular Endothelial-Cadherin Levels in Inflammatory Skin Diseases
por: Kuriyama, Haruka, et al.
Publicado: (2014)

A phase I study of the safety and efficacy of talimogene laherparepvec in Japanese patients with advanced melanoma
por: Yamazaki, Naoya, et al.
Publicado: (2022)

Intratumoral expression levels of PD-L1, GZMA, and HLA-A along with oligoclonal T cell expansion associate with response to nivolumab in metastatic melanoma
por: Inoue, Hiroyuki, et al.
Publicado: (2016)

Association of Baseline Serum Levels of CXCL5 With the Efficacy of Nivolumab in Advanced Melanoma
por: Fujimura, Taku, et al.
Publicado: (2019)

Role of inflammation in previously untreated macular edema with branch retinal vein occlusion
por: Noma, Hidetaka, et al.
Publicado: (2014)

Device-related Mycobacterium mageritense Infection in a Patient Treated with Nivolumab for Metastatic Breast Cancer
por: Koyama, Taiji, et al.
Publicado: (2021)

Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma
por: Long, Georgina V, et al.
Publicado: (2015)

Characteristics of adverse drug reactions in a vemurafenib early post-marketing phase vigilance study in Japan
por: Uhara, H., et al.
Publicado: (2017)

Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
por: Chapman, Paul B, et al.
Publicado: (2021)

A Randomized Comparison of Nivolumab versus Nivolumab + Docetaxel for Previously Treated Advanced or Recurrent ICI-Naïve Non–Small Cell Lung Cancer: TORG1630
por: Taniguchi, Yuri, et al.
Publicado: (2022)

Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up
por: Tomita, Yoshihiko, et al.
Publicado: (2019)

Temporal Trends in Grade 3/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib Versus Sunitinib for Previously Untreated Advanced Renal Cell Carcinoma
por: Geynisman, Daniel M., et al.
Publicado: (2022)

Short-term Clinical Outcome of Previously Untreated and Treated Schizophrenia and Impact of Duration of Untreated Psychosis
por: Bansal, Priyanka, et al.
Publicado: (2023)

Previously treated versus untreated scoliosis: are results different?
por: Zaina, Fabio, et al.
Publicado: (2014)

Development of a selective fluorescence-based enzyme assay for glycerophosphodiesterase family members GDE4 and GDE7
por: Kitakaze, Keisuke, et al.
Publicado: (2021)

Anti-PD-1 antibody therapy for epithelial skin malignancies: An investigator-initiated, open-label, single-arm, multicenter, phase II clinical trial (NMSC-PD1 Study)
por: Ishii, Maki, et al.
Publicado: (2020)

Efficacy and safety of nivolumab in Japanese patients with uterine cervical cancer, uterine corpus cancer, or soft tissue sarcoma: Multicenter, open‐label phase 2 trial
por: Tamura, Kenji, et al.
Publicado: (2019)

Systemic therapy for Asian patients with advanced BRAF V600‐mutant melanoma in a real‐world setting: A multi‐center retrospective study in Japan (B‐CHECK‐RWD study)
por: Namikawa, Kenjiro, et al.
Publicado: (2023)

Serum Level of Soluble CD163 May Be a Predictive Marker of the Effectiveness of Nivolumab in Patients With Advanced Cutaneous Melanoma
por: Fujimura, Taku, et al.
Publicado: (2018)

Intraoperative radiation therapy (IORT) for previously untreated malignant gliomas
por: Nemoto, Kenji, et al.
Publicado: (2002)

Pemphigus vulgaris as an immune-related adverse event in recurrent metastatic esophageal squamous cell carcinoma treated with ipilimumab plus nivolumab: a case report and literature review
por: Nakamura, Hajime, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_jt4kmditaoauieth6ag1hiqcu2